Get the Stockscreener App
1.76
2.22%
-0.04
After Hours:
1.76
Nautilus Biotechnology Inc stock is traded at $1.76, with a volume of 668.29K.
It is down -2.22% in the last 24 hours and down -24.79% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
See More
Previous Close:
$1.80
Open:
$1.77
24h Volume:
668.29K
Relative Volume:
5.79
Market Cap:
$220.99M
Revenue:
-
Net Income/Loss:
$-63.68M
P/E Ratio:
-3.7447
EPS:
-0.47
Net Cash Flow:
$-54.15M
1W Performance:
-9.74%
1M Performance:
-24.79%
6M Performance:
-30.43%
1Y Performance:
-41.33%
1-Day Range:
$1.74
$1.90
1-Week Range:
$1.74
$2.10
52-Week Range:
$1.74
$3.4547
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.76 | 220.99M | 0 | -63.68M | -54.15M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
The Manufacturers Life Insurance Company Invests $67,000 in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future - Yahoo Finance
Nautilus Biotechnology (NASDAQ:NAUT) Cut to “Sell” at The Goldman Sachs Group - Defense World
Goldman Sachs Downgrades Nautilus Biotechnology (NAUT) - MSN
Goldman Sachs cuts Nautilus Biotechnology stock to sell By Investing.com - Investing.com Canada
Goldman Sachs cuts Nautilus Biotechnology stock to sell - Investing.com
Nautilus Biotechnology Inc (NAUT-Q) QuotePress Release - The Globe and Mail
Nautilus Biotechnology Reports Q3 2024 Financial Results - MSN
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 0.8% – Here’s What Happened - Defense World
Nautilus Biotechnology (NASDAQ:NAUT) Shares Up 0.8%What's Next? - MarketBeat
3 US Penny Stocks With Market Caps Up To $400M - Simply Wall St
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award - Quantisnow
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology Co-founder and Chief Scientist Parag - GlobeNewswire
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award - Morningstar
Nautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor Scrutiny - TipRanks
Glass House Brands to Host Third Quarter 2024 Conference Call on November 13, 2024 - The Manila Times
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference - GlobeNewswire
SG Americas Securities LLC Takes Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Nautilus Biotechnology reports Q3 EPS (13c), consensus (16c) - TipRanks
Nautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Renaissance Technologies LLC Acquires 9,459 Shares of Toro Corp. (NASDAQ:TORO) - Defense World
Renaissance Technologies LLC Has $358,000 Stock Holdings in Standard Lithium Ltd. (NYSE:SLI) - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Nautilus Biotechnology Inc. - Scrip
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth - Yahoo Finance
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024 - The Manila Times
nautilus biotechnology, inc. Earnings dates - RTTNews
Clearline Capital LP Lowers Stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Tech Moves: GE healthcare exec joins startup; Nautilus taps new CMO; WRF investor steps down - MSN
Insider Selling: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells 47,031 Shares of Stock - Defense World
Nautilus Biotechnology senior VP sells over $134k in company stock - Investing.com
Caxton Associates LP Acquires 131,589 Shares of Entegris, Inc. (NASDAQ:ENTG) - Defense World
2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech
Nautilus Biotechnology senior VP sells shares worth over $99k - Investing.com India
Nautilus Biotechnology senior VP sells shares worth over $99k By Investing.com - Investing.com Canada
New CEOs at Nura, IMU - BioCentury
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer | Daily - Daily Guardian Canada
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - GlobeNewswire
Nautilus Biotechnology, Inc.'s (NASDAQ:NAUT) Top Key Executive Parag Mallick is the most upbeat insider, and their holdings increased by 11% last week - Simply Wall St
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 0.8% - MarketBeat
Who Is Jeff Bezos: History, Background, Achievements, and Net Worth - Investing.com
Dr. Parag Mallick, PhDCo-Founder, Nautilus BiotechnologyUnlocking The Complexity Of The Proteome For A New Era Of Scientific Discovery - Audacy
Nautilus Biotechnology Insider Ups Holding During Year - Yahoo Finance
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):